

REPROS THERAPEUTICS INC.

Form 8-K

February 06, 2007

**Table of Contents**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**Current Report Filed Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

**Date of Report**

**(Date of earliest event reported): February 5, 2007**

**Repros Therapeutics Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**

**(State or other jurisdiction of**

**001-15281**

**(Commission File Number)**

**76-0233274**

**(I.R.S. Employer Identification  
No.)**

**incorporation or organization)**

**2408 Timberloch Place, Suite B-7**

**The Woodlands, Texas 77380**

**(Address of principal**

**executive offices**

**and zip code)**

**(281) 719-3400**

**(Registrant's telephone**

**number, including area**

**code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**TABLE OF CONTENTS**

Item 8.01. Other Information

Item 9.01. Financial Statements and Exhibits

SIGNATURES

EXHIBIT INDEX

Press Release

---

**Table of Contents**

**Item 8.01. Other Information**

Repros Therapeutics Inc. announced yesterday that it has closed its previously announced underwritten public offering of 2,610,000 shares of its common stock at a public offering price of \$13.75 per share.

A copy of the Company's press release is attached hereto as Exhibit 99.1. The press release is incorporated by reference herein and the foregoing description of the press release is qualified in its entirety by reference to the attached exhibit.

**Item 9.01. Financial Statements and Exhibits**

c. Exhibits

Exhibit Number	Description
99.1	Press Release dated February 5, 2007.

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Repros Therapeutics Inc.**

Date: February 6, 2007.

By: /s/ Louis Ploth, Jr.

Louis Ploth, Jr.  
Vice President, Business Development and  
Chief Financial Officer

---

**Table of Contents**

**EXHIBIT INDEX**

Exhibit Number	Description
99.1	Press Release dated February 5, 2007.